Cerebral aspergillosis: Tissue penetration is the key

Medical Mycology

Volumn 47, Issue SUPPL. 1, 2009, Pages

  Schwartz, Stefan ^a   Thiel, E ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antifungal agents; Blood brain barrier; Neuroaspergillosis; Neuropharmacology

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ARTICLE; ASPERGILLOSIS; BLOOD BRAIN BARRIER; BRAIN ABSCESS; CEREBRAL ASPERGILLOSIS; CEREBROSPINAL FLUID; CRYPTOCOCCAL MENINGITIS; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOCOMPROMISED PATIENT; INTRACRANIAL HYPERTENSION; MOLECULAR SIZE; MORTALITY; NONHUMAN; PHYSICAL CHEMISTRY; SINGLE DRUG DOSE; SURVIVAL RATE; ANIMAL; REVIEW;

ANIMALIA; ASPERGILLUS;

ANIMALS; ANTIFUNGAL AGENTS; FLUCONAZOLE; HUMANS; NEUROASPERGILLOSIS; PYRIMIDINES; TRIAZOLES;

EID: 67651085693     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780802537953     Document Type: Article

References (67)

1. Walsh TJ, Hier DB, Caplan LR. Aspergillosis of the central nervous system: Clinicopathological analysis of 17 patients. Ann Neurol 1985; 18: 574-582.
2. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23: 608-615.
3. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32 358-366.
4. Pagano L, Ricci P, Montillo M, et al. Localization of aspergillosis to the central nervous system among patients with acute leukemia: Report of 14 cases. Gruppo Italiano Malattie Ematologiche dell'Adulto Infection Program. Clin Infect Dis 1996; 23: 628-630.
5. Coleman JM, Hogg GG, Rosenfeld JV, Waters KD. Invasive central nervous system aspergillosis: Cure with liposomal amphotericin B, itraconazole, and radical surgery - case report and review of the literature. Neurosurgery 1995; 36: 858-863.
6. Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005; 106: 2641-2645.
7. Mukoyama M, Gimple K, Poser CM. Aspergillosis of the central nervous system. Report of a brain abscess due to A. fumigatus and review of the literature. Neurology 1969; 19: 967-974.
8. Yamazaki T, Kume H, Murase S, Yamashita E, Arisawa M. Epidemiology of visceral mycoses: Analysis of data in annual of the pathological autopsy cases in Japan. J Clin Microbiol 1999; 37: 1732-1738.
9. Bodey G, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients: An international autopsy survey. Eur J Clin Microbiol Infect Dis 1992; 11: 99-109.
10. Jantunen E, Volin L, Salonen O, et al. Central nervous system aspergillosis in allogeneic stem cell transplant recipients. Bone Marrow Transplant 2003; 31: 191-196.
11. Hagensee ME, Bauwens JE, Kjos B, Bowden RA. Brain abscess following marrow transplantation: Experience at the Fred Hutchinson Cancer Research Center, 1984-1992. Clin Infect Dis 1994; 19: 402-408.
12. Baddley JW, Salzman D, Pappas PG. Fungal brain abscess in transplant recipients: Epidemiologic, microbiologic, and clinical features. Clin Transplant 2002; 16: 419-424.
13. Boes B, Bashir R, Boes C, et al. Central nervous system aspergillosis. Analysis of 26 patients. J Neuroimaging 1994; 4 123-129.
14. Saah D, Drakos PE, Elidan J, et al. Rhinocerebral aspergillosis in patients undergoing bone marrow transplantation. Ann Otol Rhinol Laryngol 1994; 103: 306-310.
15. Darras-Joly C, Veber B, Bedos JP, et al. Nosocomial cerebral aspergillosis: A report of 3 cases. Scand J Infect Dis 1996; 28 317-319.
16. Kim DG, Hong SC, Kim HJ, et al. Cerebral aspergillosis in immunologically competent patients. Surg Neurol 1993; 40: 326-331.
17. Gunaratne PS, Wijeyaratne CN, Seneviratne HR. Aspergillus meningitis in Sri Lanka - a post-tsunami effect? N Engl J Med 2007; 356: 754-756.
18. Torre-Cisneros J, Lopez OL, Kusne S, et al. CNS aspergillosis in organ transplantation: A clinicopathological study. J Neurol Neurosurg Psychiatry 1993; 56: 188-193.
19. Ho CL, Deruytter MJ. CNS aspergillosis with mycotic aneurysm, cerebral granuloma and infarction. Acta Neurochir (Wien) 2004; 146: 851-856.
20. Kurino M, Kuratsu J, Yamaguchi T, Ushio Y. Mycotic aneurysm accompanied by aspergillotic granuloma: A case report. Surg Neurol 1994; 42 160-164.
21. Hurst RW, Judkins A, Bolger W, Chu A, Loevner LA. Mycotic aneurysm and cerebral infarction resulting from fungal sinusitis: Imaging and pathologic correlation. AJNR Am J Neuroradiol 2001; 22: 858-863.
22. Milosev B, el Mahgoub S, Aal OA, el Hassan AM. Primary aspergilloma of paranasal sinuses in the Sudan. A review of seventeen cases. Br J Surg 1969; 56: 132-137.
23. Murthy JM, Sundaram C, Prasad VS, et al. Sinocranial aspergillosis: A form of central nervous system aspergillosis in south India. Mycoses 2001; 44: 141-145.
24. Dubey A, Patwardhan RV, Sampth S, et al. Intracranial fungal granuloma: Analysis of 40 patients and review of the literature. Surg Neurol 2005; 63: 254-260.
25. Lammens M, Robberecht W, Waer M, Carton H, Dom R. Purulent meningitis due to aspergillosis in a patient with systemic lupus erythematosus. Clin Neurol Neurosurg 1992; 94: 39-43.
26. Mikolich DJ, Kinsella LJ, Skowron G, Friedman J, Sugar AM. Aspergillus meningitis in an immunocompetent adult successfully treated with itraconazole. Clin Infect Dis 1996; 23: 1318-1319.
27. Kleinschmidt-DeMasters BK. Central nervous system aspergillosis: A 20-year retrospective series. Hum Pathol 2002; 33: 116-124.
28. Verweij PE, Brinkman K, Kremer HP, Kullberg BJ, Meis JF. Aspergillus meningitis: Diagnosis by non-culture-based microbiological methods and management. J Clin Microbiol 1999; 37: 1186-1189.
29. Hummel M, Spiess B, Kentouche K, et al. Detection of Aspergillus DNA in cerebrospinal fluid from patients with cerebral aspergillosis by a nested PCR assay. J Clin Microbiol 2006; 44 3989-3993.
30. de Boer AG, Gaillard PJ. Drug targeting to the brain. Annu Rev Pharmacol Toxicol 2007; 47: 323-355.
31. Virgintino D, Robertson D, Errede M, et al. Expression of Pglycoprotein in human cerebral cortex microvessels. J Histochem Cytochem 2002; 50: 1671-1676.
32. Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: Implications for echinocandin therapy in neonates. J Infect Dis 2008; 197: 163-171.
33. Okugawa S, Ota Y, Tatsuno K, et al. A case of invasive central nervous system aspergillosis treated with micafungin with monitoring of micafungin concentrations in the cerebrospinal fluid. Scand J Infect Dis 2007; 39: 344-346.
34. Stone JA, Xu X, Winchell GA, et al. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 2004; 48: 815-823.
35. Hajdu R, Thompson R, Sundelof JG, et al. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother 1997; 41: 2339-2344.
36. Groll AH, Mickiene D, Petraitis V, et al. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob Agents Chemother 2001; 45: 3322-3327.
37. Groll AH, Mickiene D, Petraitiene R, et al. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): Reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother 2001; 45 2845-2855.
38. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992; 326: 83-89.
39. Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000; 182: 274-282.
40. Korfel A, Menssen HD, Schwartz S, Thiel E. Cryptococcosis in Hodgkin's disease: Description of two cases and review of the literature. Ann Hematol 1998; 76: 283-286.
41. Baley JE, Meyers C, Kliegman RM, Jacobs MR, Blumer JL. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr 1990; 116: 791-797.
42. Collette N, van der Auwera P, Lopez AP, Heymans C, Meunier F. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob Agents Chemother 1989; 33: 362-368.
43. Collette N, van der Auwera P, Meunier F, et al. Tissue distribution and bioactivity of amphotericin B administered in liposomes to cancer patients. J Antimicrob Chemother 1991; 27: 535-548.
44. Perfect JR, Cox GM, Dodge RK, Schell WA. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother 1996; 40: 1910-1913.
45. van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997; 337: 15-21.
46. Perfect JR, Durack DT. Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. J Antimicrob Chemother 1985; 16: 81-86.
47. Heykants J, Michiels M, Meuldermans W, et al. The pharmacokinetics of itraconazole in animals and man: An overview. In: Fromtling RA (ed.). Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. Barcelona: J.R. Prous Science, 1987: 223-249.
48. Imai T, Yamamoto T, Tanaka S, et al. Successful treatment of cerebral aspergillosis with a high oral dose of itraconazole after excisional surgery. Intern Med 1999; 38: 829-832.
49. Miyama T, Takanaga H, Matsuo H, et al. P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. Antimicrob Agents Chemother 1998; 42: 1738-1744.
50. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immuno-compromised patients. Clin Infect Dis 2003; 37: 728-732.
51. Schwartz S, Milatovic D, Thiel E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br J Haematol 1997; 97: 663-665.
52. Elter T, Sieniawski M, Gossmann A, et al. Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman. Int J Antimicrob Agents 2006; 28: 262-265.
53. Schwartz S, Burhenne J, Haisch A, et al. Fungicidal concentrations of voriconazole in brain abscess and cerebrospinal fluid in a patient with candida meningoencephalitis. In: Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2007: M-1161.
54. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 710-718.
55. Williams PL. Coccidioidal meningitis. Ann N Y Acad Sci 2007; 1111: 377-384.
56. Stevens DA, Clemons KV. Azole therapy of clinical and experimental coccidioidomycosis. Annn N Y Acad Sci 2007; 1111: 442-454.
57. Clemons KV, Stevens DA. Comparison of fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis. Antimicrob Agents Chemother 1998; 42: 899-902.
58. Clemons KV, Sobel RA, Williams PL, Pappagianis D, Stevens DA. Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits. Antimicrob Agents Chemother 2002; 46: 2420-2426.
59. Capilla J, Clemons KV, Sobel RA, Stevens DA. Efficacy of amphotericin B lipid complex in a rabbit model of coccidioidal meningitis. J Antimicrob Chemother 2007; 60: 673-676.
60. Kamberi P, Sobel RA, Clemons KV, et al. Comparison of itraconazole and fluconazole treatments in a murine model of coccidioidal meningitis. Antimicrob Agents Chemother 2007; 51: 998-1003.
61. Chiller TM, Luque JC, Sobel RA, et al. Development of a murine model of cerebral aspergillosis. J Infect Dis 2002; 186: 574-577.
62. Zimmerli S, Knecht U, Leib SL. A model of cerebral aspergillosis in non-immunosuppressed nursing rats. Acta Neuropathol 2007; 114 411-418.
63. Chiller TM, Sobel RA, Luque JC, Clemons KV, Stevens DA. Efficacy of amphotericin B or itraconazole in a murine model of central nervous system Aspergillus infection. Antimicrob Agents Chemother 2003; 47: 813-815.
64. Clemons KV, Espiritu M, Parmar R, Stevens DA. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother 2005; 49: 4867-4875.
65. Clemons KV, Parmar R, Martinez M, Stevens DA. Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis. J Antimicrob Chemother 2006; 58: 466-469.
66. Imai J, Singh G, Fernandez B, Clemons KV, Stevens DA. Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model. J Antimicrob Chemother 2005; 56: 166-171.
67. Imai JK, Singh G, Clemons KV, Stevens DA. Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob Agents Chemother 2004; 48: 4063-4066.